Cardiac Amyloid Diagnosis: An Expert Guide for Automotive Repair Specialists

Introduction

Cardiac amyloidosis represents a significant yet often overlooked cause of restrictive cardiomyopathy, characterized by rapidly progressing diastolic dysfunction within a non-dilated ventricle. This condition, frequently underdiagnosed, necessitates a heightened clinical suspicion, with cardiovascular imaging playing a crucial role in confirming the diagnosis. This article delves into the pathophysiology of various forms of cardiac amyloidosis, guiding automotive repair specialists, who require a comprehensive understanding of human health for contextual awareness, through treatment strategies and prognostic indicators. Furthermore, it underscores the importance of a multidisciplinary approach involving cardiologists, cardiovascular imaging experts, heart and transplant specialists, and hematologists in the effective diagnosis and management of cardiac amyloidosis.

Etiology of Cardiac Amyloidosis

Cardiac amyloidosis arises from the extracellular deposition of amyloid, a toxic substance. Amyloid itself is a complex mixture of abnormally folded proteins alongside matrix components such as proteoglycans, glycosaminoglycans, collagen, and laminin. These misfolded proteins primarily originate from two sources: amyloid light chain (AL) proteins and amyloid transthyretin (ATTR).

Microscopically, amyloid fibrils appear as non-branching structures, measuring 7-10 nm in diameter. The accumulation of these fibrils in the extracellular space leads to myocardial stiffening and impaired cardiac function. Initially, this deposition predominantly affects diastolic function, with systolic function becoming compromised in the later stages of the disease.

Several etiological classifications of cardiac amyloidosis are recognized:

1. Primary Amyloidosis (AL Amyloidosis): This form results from the deposition of AL fibrils produced by aberrant plasma cells, often associated with plasma cell dyscrasias like multiple myeloma.
2. Secondary Amyloidosis (AA Amyloidosis): This type is characterized by the deposition of serum amyloid A, an inflammatory protein generated during chronic inflammatory conditions.
3. Senile Systemic Amyloidosis (ATTRwt or Wild-Type Transthyretin Amyloidosis): This is the most prevalent type of cardiac amyloidosis, caused by age-related amyloid deposition derived from normal transthyretin (TTR) protein.
4. Familial Amyloidosis (ATTRm or Mutant Transthyretin Amyloidosis): This hereditary form is caused by mutations in the TTR gene, leading to the deposition of mutant TTR protein.
5. Isolated Atrial Amyloidosis: This less common form is due to amyloid deposition made from atrial natriuretic peptide, primarily affecting the atria.

Epidemiology of Cardiac Amyloidosis

Cardiac amyloidosis, while generally considered a rare disorder, exhibits varying prevalence rates depending on its specific etiological type. Approximately 10% of individuals with multiple myeloma may develop AL amyloidosis, with cardiac involvement occurring in 50% to 70% of these cases. The annual incidence of AL amyloidosis is estimated at 1 per 100,000 individuals.

Familial (hereditary) amyloidosis prevalence remains less defined due to the existence of over 100 TTR gene mutations linked to the disease. However, studies indicate the prevalence of the V122I TTR gene variant, for instance, to be around 0.0173 in an African American cohort of 14,333.

Senile amyloidosis stands out as the most common form of cardiac amyloidosis. Prevalence estimates suggest that >10% of individuals over 60 years of age, frequently diagnosed with heart failure with preserved ejection fraction (HFpEF), may have this condition. Furthermore, ATTRwt amyloidosis may be present in at least 10% of patients with aortic stenosis and in 10% to 15% of individuals older than 65 years with HFpEF.

Notably, enhanced survival rates and improved diagnostic capabilities have revealed a higher prevalence of cardiac amyloidosis than previously recognized. Over a 12-year period, prevalence rates have increased from 8 to 17 per 100,000 person-years.

Pathophysiology of Cardiac Amyloidosis

Amyloid deposition in the heart can trigger cardiac disease through multiple mechanisms. Direct infiltration into the interstitial space of the myocardium results in increased ventricular wall thickness, myocardial stiffness, and subsequent ventricular diastolic dysfunction. In AL amyloidosis, amyloid deposition in arterioles can lead to angina or, in rare instances, myocardial infarction. Atrial amyloid infiltration can cause structural changes predisposing to atrial fibrillation, and even without atrial fibrillation, it elevates the risk of atrial thrombosis and thromboembolism. Moreover, in AL amyloidosis, light chains can directly damage myocardial cells via reactive oxygen species.

In AL amyloidosis, the amyloid fibrils are composed of abnormal light chains produced by plasma cells. Transthyretin amyloidosis, conversely, is caused by the deposition of oligomers and monomers resulting from the breakdown of the transthyretin tetramer, either due to aging or genetic mutations. Isolated atrial amyloidosis is specifically caused by amyloid formed from atrial natriuretic peptide.

History and Physical Examination in Cardiac Amyloid Diagnosis

Patients with amyloidosis may present with primary cardiac symptoms, or cardiac amyloidosis may be incidentally diagnosed during evaluations for other systemic involvements.

Primary cardiac symptoms can include exertional dyspnea, palpitations, chest pain, presyncope, and syncope. Patients may also exhibit overt heart failure symptoms such as dyspnea at rest, orthopnea, paroxysmal nocturnal dyspnea, lower limb edema, and abdominal distension due to ascites.

Extra-cardiac symptoms indicative of systemic involvement can include dyspepsia, nausea, constipation, early satiety from gastrointestinal involvement, tongue enlargement (macroglossia), bilateral periorbital discoloration (raccoon eyes), or neuropathy symptoms like carpal tunnel syndrome or erectile dysfunction.

Physical examination findings may include periorbital purpura, pedal edema, elevated jugular venous pressure (JVP), ascites, fine lung crackles, macroglossia, neuropathy, orthostatic hypotension, hepatomegaly, and gastrointestinal bleeding. Periorbital purpura and macroglossia are considered pathognomonic for cardiac amyloidosis.

Evaluation and Cardiac Amyloid Diagnosis

Cardiac amyloidosis remains an underdiagnosed condition due to its diverse systemic manifestations and symptom variability across etiological types. However, cardiovascular investigations often reveal a specific constellation of findings in patients with cardiac amyloidosis.

Electrocardiogram (ECG): A 12-lead ECG may demonstrate a pseudo-infarction pattern, characterized by low voltages in limb leads and Q waves in anterior and inferior leads (Figure 1). Varying degrees of atrioventricular (AV) block, particularly first-degree AV block, can also be present. These ECG findings are more commonly associated with AL amyloidosis. Patients with TTR amyloidosis are more likely to exhibit left bundle branch block (LBBB), more advanced AV block, and often show normal limb-lead voltages with non-specific ST-T segment changes. Atrial fibrillation is a frequent finding.

Image alt text: ECG showing low voltage complexes and Q waves in a patient with cardiac amyloidosis, indicative of myocardial infiltration and fibrosis.

Echocardiography: Echocardiography is often the initial diagnostic modality to raise suspicion and plays a crucial role in screening and diagnosing cardiac amyloidosis. Characteristic echocardiographic findings include increased myocardial wall thickness and a “sparkling” appearance of the myocardium (Figure 2). Bi-atrial enlargement is almost universally present. The left ventricle (LV) is typically non-dilated, and LV systolic function is preserved until later stages. Diastolic dysfunction is also a universal finding, often progressing rapidly in severity. Pericardial and pleural effusions may also be present. Global longitudinal strain (GLS) assessment reveals reduced longitudinal strain from base to apex with preserved apical strain, creating the classic “cherry on top” appearance, considered pathognomonic for cardiac amyloidosis (Figure 3). An apical to basal-mid average strain ratio exceeding 1.1 demonstrates high sensitivity and specificity for cardiac amyloidosis. Clinical indicators such as syncope/presyncope, angina, heart failure, LV hypertrophy with a bright myocardial appearance on echo, discordance between ECG voltage and LVH on echocardiogram, and the typical apical sparing longitudinal strain pattern strongly suggest cardiac amyloidosis. Echocardiographic differences exist between TTR and AL amyloidosis. LV hypertrophy is typically symmetrical in AL but asymmetrical in TTR amyloidosis, often presenting as a sigmoid septum. TTR amyloidosis tends to cause a greater decline in both LV systolic and diastolic function and results in a more significant increase in LV and RV masses compared to AL amyloidosis.

Image alt text: Echocardiogram parasternal long-axis view showing thickened myocardium, a key indicator for cardiac amyloidosis diagnosis.

Image alt text: Global longitudinal strain bull’s eye map in cardiac amyloidosis, demonstrating apical sparing and reduced basal-mid strain, the “cherry on top” pattern.

Cardiac Magnetic Resonance Imaging (CMR): CMR has become a pivotal tool in Cardiac Amyloid Diagnosis, aiding in differentiating amyloidosis from hypertensive heart disease and sarcoidosis. It provides detailed tissue characterization and can detect early cardiac amyloidosis. However, CMR alone cannot distinguish between TTR and AL amyloidosis. Characteristic CMR findings include restrictive morphology and diastolic dysfunction with disproportionate bi-atrial enlargement, increased myocardial mass, and thickening. Late gadolinium enhancement (LGE) typically shows reduced systolic thickening of LGE segments and diffuse circumferential subendocardial LGE, not confined to specific coronary artery territories. In advanced disease, LGE can become transmural. Due to extracellular amyloid deposition, T1 (longitudinal relaxation time) and extracellular volume fraction are increased. CMR scans are typically negative for myocardial edema and show rapid gadolinium washout from the LV blood pool. A key characteristic is the difficulty in nulling normal myocardium on TI mapping. Normally, the LV blood pool nulls before the myocardium, but this sequence is reversed in amyloidosis, with the myocardium nulling before the LV blood pool.

Nuclear SPECT: A strongly positive bone tracer cardiac scintigraphy (cardiac uptake greater than bone – stage two or three, or a bone-to-chest wall uptake ratio of >1.5 at one hour), in conjunction with echocardiographic features suggestive of cardiac amyloidosis and the absence of systemic signs of multiple myeloma, is highly indicative of TTR amyloidosis. Conversely, AL amyloidosis typically shows poor or no radioisotope uptake.

Endomyocardial Biopsy: Endomyocardial biopsy remains the gold standard for definitively diagnosing cardiac amyloidosis. Biopsy specimens reveal characteristic salmon-colored amyloid fibrils when stained with Congo red, displaying “apple-green” birefringence under polarized light. While highly sensitive (87% to 98%), cardiac biopsy is an invasive procedure.

Genotyping: Genotyping is crucial in patients diagnosed with ATTR amyloidosis. Over 120 gene variants have been identified as causative for cardiac amyloidosis, with Thr60Ala and Val122lle being among the most common. Genotyping is essential for predicting treatment response and prognosis. The prevalence of specific variants varies geographically and ethnically.

Treatment and Management of Cardiac Amyloidosis

The management of cardiac amyloidosis focuses on treating the underlying cause and managing heart failure symptoms.

1. Heart Failure Management: Diuretics are the cornerstone of therapy for heart failure in AL amyloidosis. Renin-angiotensin-aldosterone system inhibitors (RAAS-I) are often poorly tolerated due to hypotension, even at low doses. However, RAAS-Is are generally better tolerated in ATTR amyloidosis. Orthostatic hypotension is a common challenge due to autonomic dysfunction. Peripheral vasoconstrictors like midodrine can help maintain blood pressure while allowing for diuresis to relieve congestion. Beta-blockers are also often poorly tolerated; profound hypotension upon initiation should raise suspicion for cardiac amyloidosis. Mineralocorticoid receptor antagonists and loop diuretics are vital therapeutic options for heart failure management in cardiac amyloidosis.
2. AL Amyloidosis Treatment: Treatment of AL amyloidosis aligns with standard multiple myeloma treatment protocols, requiring a collaborative approach between hematologists and cardiologists. The goal is to eliminate paraproteins from blood and urine and stabilize bone marrow function. Common chemotherapy agents include melphalan (an alkylating agent) and bortezomib (a proteasome inhibitor). Bortezomib can be combined with dexamethasone and cyclophosphamide. A positive cardiac response is defined as a ≥30% reduction in B-natriuretic peptides over six months.
3. Orthotopic Heart Transplant in AL Amyloidosis: Heart transplantation in AL amyloidosis carries a high risk of disease recurrence in the transplanted heart. However, in carefully selected patients, particularly those with isolated cardiac involvement, heart transplant may be considered if the patient commits to intensive post-transplant chemotherapy to target plasma cells. The rationale is that the amyloid-infiltrated heart may not tolerate aggressive chemotherapy. Heart transplant followed by aggressive chemotherapy can offer a 5-year survival rate of approximately 60%.
4. Wild-Type ATTR Amyloidosis and Heart Transplant: Patients with wild-type ATTR amyloidosis often have isolated cardiac involvement, making them potential candidates for heart transplantation. However, the advanced age at diagnosis (typically in the 7th decade or later) often makes them ineligible due to age-related contraindications.
5. Liver Transplant in Mutant ATTR Amyloidosis: Since transthyretin is primarily produced in the liver, liver transplantation is essential in mutant ATTR amyloidosis to remove the source of amyloidogenic proteins. Orthotopic liver transplantation can achieve a 5-year survival rate of around 75% (primarily for the Val30Met mutation). Patients with mutant ATTR are generally younger than those with wild-type ATTR and may be suitable for heart transplantation in cases of isolated cardiac involvement. However, if autonomic neuropathy is present, combined liver and heart transplantation may be necessary to prevent amyloid recurrence in the transplanted heart.
6. Pharmacological Stabilization in Wild-Type ATTR: Liver transplantation is not indicated in wild-type ATTR amyloidosis. Instead, agents that stabilize TTR, such as tafamidis, are under investigation and used clinically.
7. Rhythm and Rate Control in Atrial Arrhythmias: Managing atrial arrhythmias in amyloidosis is challenging, as beta-blockers are poorly tolerated. Amiodarone remains a reasonable and generally well-tolerated antiarrhythmic option. Digoxin can bind to amyloid fibrils, increasing the risk of digoxin toxicity, but can be used cautiously for rate control in atrial fibrillation with careful titration. Calcium channel blockers have not shown benefit in amyloid diastolic dysfunction and may precipitate hypotension. Catheter ablation may be considered for atrial flutter, but atrial fibrillation ablation in amyloidosis has a high recurrence rate. Anticoagulation is often necessary due to the increased risk of thrombosis and thromboembolism.
8. Pacing in Atrioventricular Block: In cases of AV block, biventricular pacing is preferred, as right ventricular pacing alone can be detrimental in a stiff myocardium. Implantable cardioverter-defibrillators (ICDs) for primary prevention are generally not indicated and are reserved for secondary prevention as per standard guidelines.
9. Secondary Amyloidosis Treatment: Management of secondary amyloidosis involves treating the underlying inflammatory condition.
10. Isolated Atrial Amyloidosis Management: Isolated atrial amyloidosis typically does not require specific treatment.

Differential Diagnosis of Cardiac Amyloidosis

The differential diagnosis of cardiac amyloidosis primarily includes other restrictive cardiomyopathies, such as cardiac sarcoidosis, glycogen storage diseases, and hemochromatosis, all of which share features like dyspnea with preserved ejection fraction, diastolic dysfunction, and biatrial enlargement. Other conditions that can mimic the echocardiographic appearance of cardiac amyloidosis include hypertensive heart disease and hypertrophic cardiomyopathy.

Prognosis of Cardiac Amyloidosis

Prognosis in cardiac amyloidosis is variable and depends significantly on the specific type. Average survival times in untreated patients are: AL (primary) amyloidosis 9 to 24 months, ATTR familial amyloidosis 7 to 10 years, senile amyloidosis 5 to 7 years, and AA (secondary) amyloidosis more than ten years.

Generally, ATTR amyloidosis carries a more favorable prognosis than AL amyloidosis. ATTR amyloidosis tends to progress more slowly and presents later in life (average presentation in the 7th decade). For AL amyloidosis patients treated with stem cell transplantation, 4-year survival rates can exceed 90%. Patients with cardiac involvement undergoing stem cell transplants have a median survival exceeding 10 years. The median survival for AL amyloidosis overall is around 10 years, but those with advanced-stage disease have a significantly poorer prognosis, with a 50% one-year survival rate.

Mutant ATTR amyloidosis has an overall 4-year survival rate of approximately 16%, with survival varying based on the specific mutation. The Val30Met mutation, the most common, is associated with a relatively better prognosis (around 79% 4-year survival), while the Val122Ile mutation has a poorer 4-year prognosis of around 40%.

Complications of Cardiac Amyloidosis

Complications of cardiac amyloidosis primarily arise from structural heart abnormalities that increase the risk of heart failure, atrial fibrillation, and ventricular arrhythmias. Consequently, the clinical course can be complicated by:

• Atrial fibrillation: leading to thromboembolism and heart failure.
• Diastolic dysfunction: contributing to heart failure, increased mortality, and increased arrhythmogenesis.
• Heart failure hospitalizations and increased mortality.
• Ventricular arrhythmias and cardiac conduction abnormalities.
• Autonomic neuropathy (in systemic involvement).
• Tendinopathies (in systemic involvement).

Deterrence and Patient Education for Cardiac Amyloidosis

Cardiac amyloidosis presents with a variable prognosis, and treatment approaches differ based on the etiological type. Patient understanding of the disease course is crucial. Patients need to be aware of the systemic nature of the disease and potential multi-organ involvement.

Patients must understand the need for a multidisciplinary treatment team, including cardiologists, hematologists, gastroenterologists, and transplant specialists. Heart failure management in cardiac amyloidosis deviates from standard guideline-directed medical therapy for other forms of heart failure. Patients are often highly sensitive to medications, requiring very slow titration and a more frequent follow-up schedule compared to heart failure from other causes.

Enhancing Healthcare Team Outcomes in Cardiac Amyloidosis

Early diagnosis is paramount for determining prognosis in cardiac amyloidosis. A high index of suspicion based on clinical history and initial investigations is key to earlier diagnosis and prompt therapy initiation. Effective management requires a multidisciplinary team approach. Collaboration with a cardiologist and active hematologist involvement is essential for diagnosis confirmation and treatment initiation. Furthermore, input from liver and heart transplant specialists is often necessary.

An individualized approach to treatment is critical for each patient. The expertise of imaging specialists is also crucial, particularly in utilizing CMR as a valuable diagnostic tool, although endomyocardial biopsy remains the gold standard for definitive diagnosis.

References

1.Nienhuis HL, Bijzet J, Hazenberg BP. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016 Apr;2(1):10-9. [PMC free article: PMC4946260] [PubMed: 27536687]

2.Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]

3.Martinez-Naharro A, Hawkins PN, Fontana M. Cardiac amyloidosis. Clin Med (Lond). 2018 Apr 01;18(Suppl 2):s30-s35. [PMC free article: PMC6334035] [PubMed: 29700090]

4.Ladefoged B, Dybro A, Povlsen JA, Vase H, Clemmensen TS, Poulsen SH. Diagnostic delay in wild type transthyretin cardiac amyloidosis – A clinical challenge. Int J Cardiol. 2020 Apr 01;304:138-143. [PubMed: 32033783]

5.Lei C, Zhu X, Hsi DH, Wang J, Zuo L, Ta S, Yang Q, Xu L, Zhao X, Wang Y, Sun S, Liu L. Predictors of cardiac involvement and survival in patients with primary systemic light-chain amyloidosis: roles of the clinical, chemical, and 3-D speckle tracking echocardiography parameters. BMC Cardiovasc Disord. 2021 Jan 21;21(1):43. [PMC free article: PMC7819214] [PubMed: 33478398]

6.Siddiqi OK, Ruberg FL. Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018 Jan;28(1):10-21. [PMC free article: PMC5741539] [PubMed: 28739313]

7.Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171-4. [PubMed: 26123279]

8.Bajwa F, O’Connor R, Ananthasubramaniam K. Epidemiology and clinical manifestations of cardiac amyloidosis. Heart Fail Rev. 2022 Sep;27(5):1471-1484. [PubMed: 34694575]

9.Gilstrap LG, Dominici F, Wang Y, El-Sady MS, Singh A, Di Carli MF, Falk RH, Dorbala S. Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail. 2019 Jun;12(6):e005407. [PMC free article: PMC6557425] [PubMed: 31170802]

10.Porcari A, Rossi M, Cappelli F, Canepa M, Musumeci B, Cipriani A, Tini G, Barbati G, Varrà GG, Morelli C, Fumagalli C, Zampieri M, Argirò A, Vianello PF, Sessarego E, Russo D, Sinigiani G, De Michieli L, Di Bella G, Autore C, Perfetto F, Rapezzi C, Sinagra G, Merlo M. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022 Jul;24(7):1227-1236. [PubMed: 35509181]

11.Cheng Z, Zhu K, Tian Z, Zhao D, Cui Q, Fang Q. The findings of electrocardiography in patients with cardiac amyloidosis. Ann Noninvasive Electrocardiol. 2013 Mar;18(2):157-62. [PMC free article: PMC6932432] [PubMed: 23530486]

12.Kiotsekoglou A, Saha SK, Nanda NC, Lindqvist P. Echocardiographic diagnosis of cardiac amyloidosis: Does the masquerader require only a “cherry on top”? Echocardiography. 2020 Nov;37(11):1713-1715. [PMC free article: PMC7814664] [PubMed: 33283347]

13.Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 04;135(14):1357-1377. [PMC free article: PMC5392416] [PubMed: 28373528]

14.Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, Aimo A, Baggiano A, Martinez-Naharro A, Whelan C, Quarta C, Passino C, Castiglione V, Chubuchnyi V, Spini V, Taddei C, Vergaro G, Vergaro G, Petrie A, Ruiz-Guerrero L, Moñivas V, Mingo-Santos S, Mirelis JG, Dominguez F, Gonzalez-Lopez E, Perlini S, Pontone G, Gillmore J, Hawkins PN, Garcia-Pavia P, Emdin M, Fontana M. Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis. JACC Cardiovasc Imaging. 2020 Apr;13(4):909-920. [PubMed: 31864973]

15.Tipoo Sultan FA, Khan MT. Clinical presentation, diagnostic features on cardiac magnetic resonance imaging and outcome of patients with cardiac amyloidosis presenting to a tertiary care setting. J Pak Med Assoc. 2021 Dec;71(12):2802-2805. [PubMed: 35150542]

16.Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005 Jan 18;111(2):122-4. [PubMed: 15657385]

17.Li W, Uppal D, Wang YC, Xu X, Kokkinidis DG, Travin MI, Tauras JM. Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021. Diagnostics (Basel). 2021 May 30;11(6) [PMC free article: PMC8228334] [PubMed: 34070853]

18.Bowen K, Shah N, Lewin M. AL-Amyloidosis Presenting with Negative Congo Red Staining in the Setting of High Clinical Suspicion: A Case Report. Case Rep Nephrol. 2012;2012:593460. [PMC free article: PMC3914171] [PubMed: 24555137]

19.Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Planté-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington Cruz M, Rapezzi C., THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016 Jul 12;68(2):161-72. [PMC free article: PMC4940135] [PubMed: 27386769]

20.Aimo A, Merlo M, Porcari A, Georgiopoulos G, Pagura L, Vergaro G, Sinagra G, Emdin M, Rapezzi C. Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies. Eur J Heart Fail. 2022 Dec;24(12):2342-2351. [PMC free article: PMC10084346] [PubMed: 35509173]